- Altasciences has expanded its drug product formulation and manufacturing services facility in Harleysville, Pennsylvania, adding approximately 768 square feet of R&D laboratory space.
- The expansion integrates formulation development and analytical testing to support early-stage drug development for small molecules, peptides, and complex modalities.
Altasciences has expanded the research and development laboratory at its drug product formulation and manufacturing services facility in Harleysville, Pennsylvania, adding approximately 768 square feet of laboratory space. The expansion integrates formulation development and analytical testing within a single laboratory to support earlier-stage drug development and strengthen its contract development and manufacturing organization (CDMO) capabilities.
According to the company, the integrated laboratory is designed to accelerate decision-making, streamline workflows, and improve collaboration across scientific disciplines. The facility supports phase-appropriate, target product profile (TPP)-driven formulation screening for a range of therapeutic areas and routes of administration. Its capabilities include formulation development for small molecules, peptides, and complex modalities, as well as preparation of non-GLP and GLP toxicology samples for nonclinical studies.
“With this expansion, we are strengthening our focus on early-stage integration, bringing our CDMO capabilities to clients earlier in the drug development journey. This enhances continuity across nonclinical and clinical programs, helping clients navigate key development milestones more efficiently and effectively.”
Anuji Abraham, Senior Director, Pharmaceutical Development, CDMO Services at Altasciences
The expanded laboratory also provides advanced screening models and integrated analytical testing to support nonclinical and clinical readiness, while allowing real-time formulation decisions. Operating in a non-GLP R&D environment, the facility enables clients to optimize products before transitioning into regulated studies. Altasciences said the investment also includes expanding its scientific team to support clients throughout the drug development process.
